Finch Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Finch Therapeutics's estimated annual revenue is currently $19.5M per year.
- Finch Therapeutics received $36.0M in venture funding in March 2018.
- Finch Therapeutics's estimated revenue per employee is $697,500
- Finch Therapeutics's total funding is $188.8M.
- Finch Therapeutics's current valuation is $432.1M. (January 2022)
- Finch Therapeutics has 28 Employees.
- Finch Therapeutics grew their employee count by -49% last year.
Finch Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Finch Therapeutics?
Finch Therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. We use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients lives.keywords:Pharmaceuticals
Number of Employees
Employee Growth %
Finch Therapeutics News
The workforce reduction, which will impact 37 employees, follows Finch's recent move to pause its chronic hepatitis B program, the clinical hold...
Finch Therapeutics reported Tuesday morning that it would be laying off 37 staffers, or approximately 20% of its workforce,...
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class...
Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90 million Series D funding round Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90 million Series D funding round. New investors in this ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Finch Therapeutics Funding